ADMA Biologics (NASDAQ:ADMA) Shares Up 4.6% - Still a Buy?

Key Points

• ADMA Biologics shares rose 4.6% to about $9.81 in mid-day trading, though volume was 77% below the average session level.
• Analyst sentiment is moderately positive: the stock has an average “Moderate Buy” rating and an average price target of $18.67, despite Mizuho cutting its target to $17.
• The company met quarterly EPS expectations at $0.16, while revenue reached $124.39 million, up 2% year over year but slightly below estimates. Institutional investors own 75.68% of the outstanding shares.

ADMA Biologics Inc (NASDAQ:ADMA - Get Free Report) traded up 4.6% during mid-day trading on Monday. The company traded as high as $9.74 and last traded at $9.8090. 992,204 shares were traded during trading, a decline of 77% from the average session volume of 4,236,085 shares. The stock had previously closed at $9.38.

Wall Street Analyst Weigh In

Several equities research analysts have weighed in on the stock. Mizuho cut their target price on shares of ADMA Biologics from $20.00 to $17.00 and set an "outperform" rating on the stock in a report on Wednesday, July 15th. Zacks Research raised ADMA Biologics from a "strong sell" rating to a "hold" rating in a research note on Wednesday, September 2nd. Raymond James Financial initiated coverage on ADMA Biologics in a research note on Wednesday, June 10th. They issued an "outperform" rating and a $21.00 target price for the company. Finally, Weiss Ratings reaffirmed a "hold (c)" rating on shares of ADMA Biologics in a research report on Monday, September 14th. Three analysts have rated the stock with a Buy rating and three have given a Hold rating to the stock. Based on data from MarketBeat.com, the company presently has an average rating of "Moderate Buy" and an average price target of $18.67.

ADMA Biologics Stock Performance

The stock's 50-day moving average price is $9.28 and its 200 day moving average price is $9.57. The firm has a market cap of $2.26 billion, a P/E ratio of 14.51 and a beta of 0.78. The company has a debt-to-equity ratio of 0.49, a current ratio of 6.97 and a quick ratio of 3.81.

ADMA Biologics (NASDAQ:ADMA - Get Free Report) last issued its quarterly earnings results on Wednesday, August 5th. The biotechnology company reported $0.16 EPS for the quarter, meeting the consensus estimate of $0.16. The firm had revenue of $124.39 million during the quarter, compared to analysts' expectations of $125.34 million. ADMA Biologics had a return on equity of 40.17% and a net margin of 32.98%.The business's quarterly revenue was up 2.0% compared to the same quarter last year. During the same period in the prior year, the firm posted $0.14 earnings per share. As a group, equities analysts predict that ADMA Biologics Inc will post 0.78 EPS for the current year.

Hedge Funds Weigh In On ADMA Biologics

A number of institutional investors have recently added to or reduced their stakes in the company. Royal Bank of Canada lifted its holdings in ADMA Biologics by 448.8% during the 1st quarter. Royal Bank of Canada now owns 929,326 shares of the biotechnology company's stock valued at $8,373,000 after purchasing an additional 759,984 shares during the last quarter. Bank of America Corp DE increased its holdings in shares of ADMA Biologics by 107.5% in the first quarter. Bank of America Corp DE now owns 3,997,675 shares of the biotechnology company's stock valued at $36,019,000 after purchasing an additional 2,071,338 shares during the last quarter. Louisiana State Employees Retirement System bought a new position in shares of ADMA Biologics in the first quarter valued at about $951,000. BNP Paribas Financial Markets raised its position in shares of ADMA Biologics by 2,188.4% in the fourth quarter. BNP Paribas Financial Markets now owns 1,141,106 shares of the biotechnology company's stock valued at $20,814,000 after purchasing an additional 1,091,241 shares during the period. Finally, Y Intercept Hong Kong Ltd lifted its stake in shares of ADMA Biologics by 1,508.1% during the 1st quarter. Y Intercept Hong Kong Ltd now owns 1,075,422 shares of the biotechnology company's stock worth $9,690,000 after buying an additional 1,008,548 shares during the last quarter. 75.68% of the stock is currently owned by institutional investors and hedge funds.

About ADMA Biologics

ADMA Biologics, Inc is a biopharmaceutical company focused on developing, manufacturing and marketing plasma-derived biologic products for patients with compromised or inadequate immune systems. The company's activities include operating plasma collection centers, sourcing human plasma, and producing specialized immunoglobulin therapies.

ADMA's marketed products include ASCENIV, an intravenous immune globulin indicated for the treatment of primary humoral immunodeficiency disease; BIVIGAM, an intravenous immune globulin for primary humoral immunodeficiency; and Nabi-HB, a hepatitis B immune globulin used to provide protection against hepatitis B infection in certain clinical settings.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.